Inozyme Pharma, Inc.
NASDAQ:INZY
1.41 (USD) • At close January 24, 2025
Overzicht | Financiële gegevens
Bedrijfsnaam | Inozyme Pharma, Inc. |
Symbool | INZY |
Munteenheid | USD |
Prijs | 1.41 |
Beurswaarde | 90,578,682 |
Dividendpercentage | 0% |
52-weken bereik | 1.235 - 7.795 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Douglas A. Treco Ph.D. |
Website | https://www.inozyme.com |
Over Inozyme Pharma, Inc.
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)